1 / 34

February 2013

February 2013. BioGaia – a healthcare company in probiotics. Vision : BioGaia´s vision is to improve the health of people around the world by offering first class probiotic products.

scot
Download Presentation

February 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. February 2013

  2. BioGaia – a healthcare company in probiotics Vision: BioGaia´s vision is to improve the health of people around the world by offering first class probiotic products. Business concept: BioGaia´s concept is to develop, market and sell well documented probiotic products worldwide in the form of innovative and appealing dietary supplements and food products. Probiotics:Live microorganisms which when administered in adequate amounts confer a documented health benefit.

  3. BioGaia • Founded in 1990 • Probiotics (strains of Lactobacillus reuteri) • 79 employees (Stockholm 31, Lund 23, Eslöv 16, Raleigh 2, Hiroshima 6, Shanghai 1) • Two segments: Finished consumer products/Component products • More than 100 clinical studies • Products in 60 markets through distributors • Contract manufacturing • TwoPac (50% owned) • Holds over 200 patents in 25 families

  4. Change of focus Dietary Supplements Infant formula Functional Foods / Dairies Animal Health 1990 1995 2000 2005 2010

  5. Business model – three networks

  6. Distribution partner network

  7. BioGaia Brand • Branding for Health professionals • Sold in over 40 countries • 45% of sales of finished products (incl. co- branding 51%) • Build value, less dependence on distributors and patents

  8. Competition Strategy • Clinical trials of high quality • Attractive and unique formulations and packaging solutions • Strong partner support

  9. Scientific network

  10. Clinical trials supporting the use of BioGaia Probiotics with L. reuteri – including the strains L. reuteri Protectis, Prodentis and Gastrus • Completed clinical trialsNov. 2012 • 108 trials in 8600 individuals • whereof: • 76 randomised, double-blind / blind, placebo-controlled studies in 6 800 subjects • 32 open studies in 1 770 subjects • 35 studies in 0-3y in 3 900 subjects Results are published in67scientific articles and 5 doctoral theses

  11. Product Indications Overview L. reuteri DSM 17938 (ATCC 55730) • BioGaia ProTectis (82*) Gut Motility Diarrhoea Neonatal Intensive Care Regurgitation Necrotising Enterocolitis Prevention Gingivitis/plaque Infantile colic Acute Gastroenteritis Periodontitis Antibiotic AssociatedDiarrhoea (AAD) Constipation Feeding tolerance Functional abdominal Pain (FAP) • BioGaia ProDentis (22*) L. reuteri DSM 17938 & L. reuteri ATCC PTA 5289 L. reuteri DSM 17938 & L. reuteri ATCC PTA 6485 • BioGaia Gastrus (2*) Gum Integrity Stomach Health H. Pylori infection/inflammation H. pylori side effects * Number of completedclinical studies byNov 2012

  12. Health protection by L. reuteri Protectisin children Children (4-10 m) with increasedrisk for infection12 weekssupplementationin baby formula Weizman et al., Pediatr 115; 5-9 (2005)

  13. Health economics of L. reuteri Protectissupplementation Children (4-10 m) with increasedrisk for infection12 weekssupplementationin baby formula Weizman et al., Pediatr 115; 5-9 (2005)

  14. L. reuteri Protectisprevents antibiotic- associated diarrhoea Adults in hospital on antibiotics Supplemented with L. reuteri Protectisor placebo for 4 weeks Cimperman et al. ASPEN meeting February 2009

  15. L. reuteri Protectisreduces infantile colic ** *** Crying time (median; mins/day) *** *** ** *** p< 0.01 p< 0.001 Days of supplementation Savino et al. Pediatr Res 58: 411 (2005) Savino et al. Pediatr, in press (2006)

  16. Attractive and unique formulations and packaging solutions

  17. BioGaia product portfolio ProTectis Digestive Health ProDentis OralHealth Gastrus Stomach Health ProTectis Baby ProTectis D3 Baby ProTectis Junior ProTectis Baby/Junior ProTectis ProDentis ProDentis Gastrus Drops Lozenges Tablets Tablets ORS Tablets Drops Drops

  18. Strong partner support • Clinical trials • Marketing and PR support • BioGaia Academy • Web site • Participation in conferences • Speakers at symposiums • Education of sales representatives

  19. Competitors Culture suppliers • Chr Hansen • Danisco • InstitutRosellLallemand (France) Probiotic strains • Valio (Finland) • Probi (Sweden) Functional Foods • Danone • Yakult Pharma • Merck (Germany) • Novartis • Sanofi Aventis • Ferrosan (Pfizer) Other • P&G • Local competitors

  20. Launches and planned launches • Drops: Launched in 56 countries (contracts but not launched in 15countries) • Tablets: Launched in 47 countries (contracts but not launched in 20 countries) • ORS: Launched in 6 countries (contracts but not launched in 7 countries) • Oral health products: Launched in 19 countries (contracts but not launched in 4 countries)

  21. Key events 2012 • BioGaia extends collaboration with Nestlé • Agreement with Gerber for sales of drops and ORS in United States • Agreement with Nestlé for sales of drops in Mexico • Agreement for oral health products in Czech Republic, the Benelux countries, South Africa, Singapore and Israel • Agreement for tablets and drops in Taiwan and Pakistan

  22. Key events 2012 (cont’d) • Study in type 2 diabetes started • 19 Published studies: • For example: • Study on reduction of diarrhoea in children • New confirming study on colic • Two studies on NEC in premature infants • Study on Periodontitis

  23. Nestlé Agreement • Sale of licence for EUR 50.8 (EUR 40 million paid and accounted for in q1 2012) • Further projects will be announced closer to launch (USA and Mexico) • Revenue from Nestlé is estimated in 2012 (excluding the up-front payment) to 50% of sales during 2011, in 2013 close to 2011 level and from 2014 and forward more than 2011

  24. Sales development (excl. licence revenue 2012) +33% -8% *) +36% Average growth: 24% *) Excluding licence revenue of SEK 356 million from Nestlé

  25. Sales development Finished consumer products +10% +39% +46% Average growth: 27%

  26. Income statement 2012vs2011

  27. Balance sheet 31 December 2012 (MSEK)

  28. Sales per segment (MSEK) (License revenue excluded) quarter 4 and 2012

  29. Quarterly development q1 2009- q4 2012 (rolling 12 months) (MSEK) (License revenue excluded)

  30. Sales per segment q1 2009- q4 2012 (rolling 12 months) (MSEK) (License revenue excluded)

  31. Sales per geographical market(MSEK)

  32. The Board Jörgen Thorball Inger Holmström David Dangoor Chairman Paula Zeilon Jan Annwall Stefan Elving Thomas Flinck

  33. Major Shareholders 31 December 2012 Total number of shareholders 31 December 2012: 7,384 Foreign owners: 43% of capital (31% of votes)

  34. Present focus • Continued focus on BRIC-countries and US • A number of development projects with Nestlé • Business model for Oral Health

More Related